Jazz Pharmaceuticals (JAZZ) Research & Development (2010 - 2026)

Jazz Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $196.0 million for Q1 2026.

• On a quarterly basis, Research & Development rose 8.47% year-over-year to $196.0 million in Q1 2026; TTM through Mar 2026 was $798.1 million, a 5.2% decrease from a year earlier, with the FY2025 full-year figure at $782.7 million, down 11.46% from the prior year.
• Research & Development retreated to $196.0 million in Q1 2026 per JAZZ's latest filing, from $213.9 million in the prior quarter.
• Across five years, Research & Development topped out at $240.5 million in Q4 2024 and bottomed at $130.0 million in Q1 2022.
• The 5-year median for Research & Development is $198.2 million (2025), against an average of $194.3 million.
• Across the five-year window, Research & Development surged 69.75% in 2022 and slipped 18.91% in 2025, its largest moves.
• Year by year, Research & Development stood at $172.6 million in 2022, then grew by 25.53% to $216.6 million in 2023, then advanced by 11.03% to $240.5 million in 2024, then fell by 11.06% to $213.9 million in 2025, then fell by 8.37% to $196.0 million in 2026.
• Per Business Quant, the three latest JAZZ Research & Development figures stand at $196.0 million (Q1 2026), $213.9 million (Q4 2025), and $198.2 million (Q3 2025).